European Organisation for Research and Treatment of Cancer - EORTC: Sarcoma trials

The registry lists 22 Sarcoma studies with European Organisation for Research and Treatment of Cancer - EORTC as lead sponsor. 0 are open to participants now and 1 have results posted.

Phase 1 2Phase 2 12Phase 3 9No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Surgery With or Without Radiation Therapy in Untreated Nonmetastatic Retroperitoneal SarcomaCompletedNCT01344018Not applicableResults posted
• A 3 Arm Randomized Study on Health-related QoL of Elderly Patients With Advanced Soft Tissue SarcomaTerminatedNCT04780464Phase 3
• Trabectedin Maintenance Post 1st-line in STSTerminatedNCT02929394Phase 3
• Ph II Nintedanib vs. Ifosfamide in Soft Tissue SarcomaTerminatedNCT02808247Phase 2
• CREATE: Cross-tumoral Phase 2 With CrizotinibCompletedNCT01524926Phase 2
• Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue SarcomaTerminatedNCT01189253Phase 2/3
• BI 2536 in Treating Patients With Recurrent or Metastatic Solid TumorsCompletedNCT00526149Phase 2
• Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue SarcomaStatus unknownNCT00410462Phase 2
• Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans or Giant Cell FibroblastomaCompletedNCT00085475Phase 2
• Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue SarcomaCompletedNCT00061984Phase 3
• Gefitinib in Treating Patients With Locally Advanced or Metastatic Synovial SarcomaCompletedNCT00052754Phase 2
• Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue SarcomaCompletedNCT00041249Phase 2
• Exatecan Mesylate in Treating Patients With Advanced Soft Tissue SarcomaCompletedNCT00041236Phase 2
• Liposomal Doxorubicin Plus Ifosfamide in Treating Patients With Advanced or Metastatic Soft Tissue SarcomaCompletedNCT00030784Phase 1
• Chemotherapy in Treating Patients With Metastatic Ewing's Sarcoma or Primitive Neuroectodermal TumorTerminatedNCT00014313Phase 2
• STI571 in Treating Patients With Recurrent or Refractory Soft Tissue SarcomaCompletedNCT00006357Phase 1/2
• Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue SarcomaCompletedNCT00003939Phase 2
• Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue SarcomaCompletedNCT00003212Phase 3
• Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue SarcomaCompletedNCT00003052Phase 3
• Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue SarcomaCompletedNCT00002764Phase 3
• Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue SarcomaCompletedNCT00002641Phase 3
• Radiation Therapy or No Further Treatment Following Surgery in Treating Patients With Cancer of the UterusCompletedNCT00002459Phase 3